S&P 500   4,655.27
DOW   35,135.94
QQQ   399.69
S&P 500   4,655.27
DOW   35,135.94
QQQ   399.69
S&P 500   4,655.27
DOW   35,135.94
QQQ   399.69
S&P 500   4,655.27
DOW   35,135.94
QQQ   399.69

uniQure Stock Forecast, Price & News

-0.30 (-1.04%)
(As of 11/29/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
420,777 shs
Average Volume
474,472 shs
Market Capitalization
$1.32 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive QURE News and Ratings via Email

Sign-up to receive the latest news and ratings for uniQure and its competitors with MarketBeat's FREE daily newsletter.

uniQure logo

About uniQure

uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.


Mac Jones leading the NFL in unique passing category - Patriots Wire
November 29, 2021 |  patriotswire.usatoday.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$37.51 million
Book Value
$12.78 per share


Net Income
$-125.02 million
Pretax Margin




Free Float
Market Cap
$1.32 billion

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.43 out of 5 stars

Medical Sector

153rd out of 1,392 stocks

Pharmaceutical Preparations Industry

62nd out of 670 stocks

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -

uniQure (NASDAQ:QURE) Frequently Asked Questions

Is uniQure a buy right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for uniQure in the last year. There are currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" uniQure stock.
View analyst ratings for uniQure
or view top-rated stocks.

How has uniQure's stock price been impacted by Coronavirus (COVID-19)?

uniQure's stock was trading at $47.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, QURE shares have decreased by 40.0% and is now trading at $28.52.
View which stocks have been most impacted by COVID-19

When is uniQure's next earnings date?

uniQure is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for uniQure

How were uniQure's earnings last quarter?

uniQure (NASDAQ:QURE) released its quarterly earnings results on Sunday, October, 24th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.05) by $0.26. The biotechnology company had revenue of $2 million for the quarter, compared to analyst estimates of $2.13 million. uniQure had a net margin of 64.09% and a trailing twelve-month return on equity of 75.59%. The business's revenue was up 11.1% on a year-over-year basis. During the same period last year, the firm earned ($1.21) earnings per share.
View uniQure's earnings history

What price target have analysts set for QURE?

12 Wall Street analysts have issued 12-month target prices for uniQure's stock. Their forecasts range from $27.46 to $95.00. On average, they anticipate uniQure's stock price to reach $60.15 in the next twelve months. This suggests a possible upside of 110.9% from the stock's current price.
View analysts' price targets for uniQure
or view top-rated stocks among Wall Street analysts.

Who are uniQure's key executives?

uniQure's management team includes the following people:

What is Matthew Kapusta's approval rating as uniQure's CEO?

8 employees have rated uniQure CEO Matthew Kapusta on Glassdoor.com. Matthew Kapusta has an approval rating of 74% among uniQure's employees.

What other stocks do shareholders of uniQure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other uniQure investors own include Empire Resorts (NYNY), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), AbbVie (ABBV), GW Pharmaceuticals (GWPH), NVIDIA (NVDA), Exelixis (EXEL), Square (SQ) and bluebird bio (BLUE).

What is uniQure's stock symbol?

uniQure trades on the NASDAQ under the ticker symbol "QURE."

Who are uniQure's major shareholders?

uniQure's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.18%), Invesco Ltd. (4.97%), Point72 Asset Management L.P. (1.85%), Bank of New York Mellon Corp (1.81%), 683 Capital Management LLC (1.54%) and Nordea Investment Management AB (1.20%). Company insiders that own uniQure stock include Alexander Edward Kuta III, Christian Klemt, Deventer Sander Van, Jack Kaye, Matthew C Kapusta, Paula Soteropoulos, Philip Astley-Sparke, Ricardo Dolmetsch and Robert Gut.
View institutional ownership trends for uniQure

Which major investors are selling uniQure stock?

QURE stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Invesco Ltd., Credit Suisse AG, Artisan Partners Limited Partnership, Assenagon Asset Management S.A., International Biotechnology Trust PLC, Verition Fund Management LLC, and Caption Management LLC. Company insiders that have sold uniQure company stock in the last year include Alexander Edward Kuta III, Christian Klemt, Matthew C Kapusta, Ricardo Dolmetsch, and Robert Gut.
View insider buying and selling activity for uniQure
or view top insider-selling stocks.

Which major investors are buying uniQure stock?

QURE stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., 683 Capital Management LLC, Nordea Investment Management AB, Principal Financial Group Inc., Morgan Stanley, Connor Clark & Lunn Investment Management Ltd., Bank of New York Mellon Corp, and Pacer Advisors Inc..
View insider buying and selling activity for uniQure
or or view top insider-buying stocks.

How do I buy shares of uniQure?

Shares of QURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is uniQure's stock price today?

One share of QURE stock can currently be purchased for approximately $28.52.

How much money does uniQure make?

uniQure has a market capitalization of $1.32 billion and generates $37.51 million in revenue each year. The biotechnology company earns $-125.02 million in net income (profit) each year or $6.80 on an earnings per share basis.

How many employees does uniQure have?

uniQure employs 332 workers across the globe.

What is uniQure's official website?

The official website for uniQure is www.uniqure.com.

Where are uniQure's headquarters?

uniQure is headquartered at PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP.

How can I contact uniQure?

uniQure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The biotechnology company can be reached via phone at (120) 240-6000, via email at [email protected], or via fax at 31-20-566-9272.

This page was last updated on 11/30/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.